Detail akcie Novo Nordisk Depository Receipt online

Business Summary: Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Novo Nordisk A/S (ADR) revenues increased 25% to DKR290.4B. Net income increased 21% to DKR100.99B. Revenues reflect Diabetes and obesity segment increase of 26% to DKR271.76B, Rare disease segment increase of 9% to DKR18.64B, USA segment increase of 31% to DKR167.4B, EMEA segment increase of 19% to DKR60.4B, Rest of World segment increase of 19% to DKR33.33B.